Fig. 1
From: BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Chemotherapy combined with anti-BTLA Ab significantly reduced peritoneal tumor volumes and extended survival of tumor-bearing mice. a Diagrammatic representation of different treatment protocols using paclitaxel and/or anti-BTLA Ab. Note: G1: PBS only; G2: paclitaxel 6 mg/kg; G3: anti-BTLA Ab 10 μg/mouse; G4: anti-BTLA Ab 20 μg/mouse; G5: paclitaxel 6 mg/kg and anti-BTLA Ab 10 μg/mouse; G6: paclitaxel 6 mg/kg and anti-BTLA Ab 20 μg/mouse. b Representative luminescence images of mice in various groups using the IVIS system on the indicated days after tumor challenge. (5 mice in each group) c Luminal analyses of tumor volumes in tumor-bearing mice with various regimens. Mice treated with paclitaxel and anti-BTLA Ab 20 μg/mouse exhibited the least luminescence (p < 0.001, Kruskal-Wallis test). (5 mice in each group). d Survival analysis of mice in the various groups. All mice treated with paclitaxel and anti-BTLA Ab 20 μg/mouse and 40% of mice treated with paclitaxel and anti-BTLA Ab 10 μg/mouse were alive 100 days after the WF-3/Luc tumor challenge. However, none of the mice in the other groups survived more than 70 days of tumor challenge (p < 0.001, log-rank test). (5 mice in each group)